Bill McGovern

• 

  Raymond James’ Retention Deal May Help It Keep Morgan Keegan Reps

  By Janet Levaux, AdvisorOne  |  January 27, 2012

  The $300,000 production level for the awards should prove advantageous to Raymond James, recruiters and others explain.

• 

  Regions' Latest Move Could Propel Sale of Morgan Keegan, Say Experts

  By Janet Levaux, AdvisorOne  |  October 24, 2011

  Regions Financial Corp. is offering potential suitors for its Morgan Keegan broker-dealer up to $200 million in financing, according to a report released Sunday.

• Q2 ’11 Earnings: Mixed Wirehouse Results as Wealth-Management Units Improve Sales

  By Janet Levaux, AdvisorOne  |  September 1, 2011

• 

  Securities America Deal: ‘Huge Gamble’ for Advisors and Ladenburg, Experts Say

  By Janet Levaux, AdvisorOne  |  August 17, 2011

  Recruiters are concerned that the deal will be good for Ameriprise but leave advisors in the cold, leaving them with uncertainty and lacking in better services and products.

• 

  Wirehouse Q2 Earnings Analysis: UBS Outpacing Rivals

  By Janet Levaux, AdvisorOne  |  August 5, 2011

  The Americas operations of UBS are ahead of all the wirehouses in new assets and net new money per advisor.

• Few Buyers for Exiting Broker-Dealers

  By Janet Levaux, AdvisorOne  |  July 28, 2011

  While rumors persist about possible suitors for Securities America, Morgan Keegan and other broker-dealers on the market, experts say the pool of buyers has shrunk dramatically over the past few years.

• Hard Time for BDs on the Block to Find Suitors

  By Janet Levaux, AdvisorOne  |  July 26, 2011

• 

  Sale of Securities America, Morgan Keegan Hindered by Weak M&A Environment

  By Janet Levaux, AdvisorOne  |  June 30, 2011

  Continuing liabilities and other fallout from the financial crisis has limited the pool of potential broker-dealer suitors.

• 

  The New Wirehouse World

  By Janet Levaux, AdvisorOne  |  May 1, 2011

• 

  Sale of Securities America: Advisors Should ‘Run,’ Recruiter Says

  By Janet Levaux, AdvisorOne  |  April 27, 2011

  Advisors with the IBD, which Ameriprise is selling, need to look at which options are best for them and their clients.